COMPREHENSIVE CANCER CARE NETWORK - A PILOT MODEL
CCCN pilot model
Interactive data views
Cancer epidemiology
Regional benchmarking
Cancer diagnostics
Data-based reports
Results, publishing
Presentation settings
File name
Title on the main slide
Subtitle on the main slide
Footer settings
Footer text
Date
Page number
Analyses to include
Incidence rates in regions
Mortality rates in regions
Export section report
Incidence rates in regions
Mortality rates in regions
C53 - Malignant neoplasm of cervix uteri - Incidence
Specify the patient
Sex
Age
Region
Period
Clinical stage
TNM
Analysis settings
Analysis settings
Change diagnosis
Export options
Applied filters (
reset filters
)
Sex:
|
Age:
|
Period:
|
Clinical stage:
|
T:
|
N:
|
M:
C53 – N = 40,864
Region - code
Region - name
Incidence
PHA
Capital of Prague
6,218
STC
Central Bohemian Region
4,253
JHC
South Bohemian Region
2,334
PLK
Plzen Region
2,350
KVK
Karlovy Vary Region
1,761
ULK
Usti nad Labem Region
4,525
LBK
Liberec Region
1,745
HKK
Hradec Kralove Region
1,914
PAK
Pardubice Region
1,512
VYS
Vysocina Region
1,281
JHM
South Moravian Region
4,310
OLK
Olomouc Region
2,030
ZLK
Zlin Region
1,859
MSK
Moravian-Silesian Region
4,772
C53 - Malignant neoplasm of cervix uteri - Mortality
Specify the patient
Sex
Age
Region
Period
Clinical stage
TNM
Analysis settings
Analysis settings
Change diagnosis
Export options
Applied filters (
reset filters
)
Sex:
|
Age:
|
Period:
|
Clinical stage:
|
T:
|
N:
|
M:
C53 – N = 17,039
Region - code
Region - name
Mortality
PHA
Capital of Prague
2,747
STC
Central Bohemian Region
1,845
JHC
South Bohemian Region
806
PLK
Plzen Region
933
KVK
Karlovy Vary Region
749
ULK
Usti nad Labem Region
2,074
LBK
Liberec Region
800
HKK
Hradec Kralove Region
789
PAK
Pardubice Region
587
VYS
Vysocina Region
536
JHM
South Moravian Region
1,648
OLK
Olomouc Region
830
ZLK
Zlin Region
711
MSK
Moravian-Silesian Region
1,984
Please select sex
men
women
both sexes
Please specify the age group (in years of age)
Lower limit
---Choose from---
0–4
5–9
10–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65–69
70–74
75–79
80–84
85+
Upper limit
---Choose to---
0–4
5–9
10–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65–69
70–74
75–79
80–84
85+
Please select period
From
---Choose from---
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
To
---Choose to---
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
Please select clinical stage
stage I
stage II
stage I+II
stage III
stage IV
stage III+IV
stage not available for objective reasons
stage not available – incomplete record
stage not available
all stages
Please select characteristics of the primary tumour (T)
0
1
2
3
4
S
X
all
Please select characteristics of regional lymph nodes (N)
0
1
2
3
4
X
all
Please select characteristics of distant metastases (M)
0
1
X
all
Analysis settings
Please select prevalence type
point
interval
Please select units
absolute numbers
per 100,000 population
Copy & share this analysis